DUBLIN, Aug. 23, 2023 /PRNewswire/ — Today, Medtronic announced the outcome of the U.S. Food & Drug Administration (FDA) Circulatory System Devices Panel (CSDP) meeting to review data presented in support of the Medtronic Symplicity Spyral™ Renal Denervation (RDN) System. The panel […]
Tag: Renal Denervation
ReCor Responds to European Society of Hypertension’s (ESH) Updated Guidelines for Management of Arterial Hypertension
PALO ALTO, Calif.–(BUSINESS WIRE)–ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) are pleased to see the updated and expanded recommendations for the management of arterial hypertension that The European Society of Hypertension (ESH) […]
Verve Medical Announces FDA Approval of IDE for Pivotal Trial of RPD™ Renal Pelvic Denervation System for Treatment of Uncontrolled Hypertension
PHOENIX–(BUSINESS WIRE)–Verve Medical, Inc. (Verve) announced today that the Company has received approval from the US Food & Drug Administration (FDA) to initiate its Natural Orifice via renal pelvis denervation (NOVEL- Denervation) Pivotal IDE trial for the treatment of uncontrolled […]
ReCor Medical Announces FDA Approval Of IDE For Pivotal Study Of Paradise® Ultrasound Denervation System For Treatment Of Hypertension
PALO ALTO, Calif., July 2, 2018 /PRNewswire/ — ReCor Medical announced today that the US Food & Drug Administration approved the Company’s new pivotal study of the Paradise Ultrasound Denervation System for the treatment of hypertension: RADIANCE-II. Building upon the recent positive […]
ReCor Medical Announces Completion of RADIANCE-HTN SOLO Hypertension Study
PALO ALTO, Calif., Jan. 5, 2018 /PRNewswire-USNewswire/ — ReCor Medical announced today randomization of its 146th, and final, subject in the SOLO cohort of its RADIANCE-HTN study. RADIANCE-HTN, ReCor’s study of its Paradise Renal Denervation System in people with hypertension, involves two […]
ReCor Medical Announces 1000th Enrollment and 150th Randomization in RADIANCE-HTN Hypertension Study
PALO ALTO, Calif., Oct. 30, 2017 /PRNewswire-USNewswire/ — ReCor Medical announced progress milestones in the study of its Paradise® Renal Denervation System as a potential treatment for hypertension, including the 1000th consented and the 150th randomized subjects in the RADIANCE-HTN study, and […]
Medtronic Plans for Renal Denervation Pivotal Trial After New Study Shows Significant Blood Pressure Reductions
Published Simultaneously in The Lancet, the Late-Breaking SPYRAL HTN-OFF MED Study at ESC Successfully Isolates RDN Treatment Effect to Show Compelling Efficacy and Safety of Hypertension Procedure DUBLIN and BARCELONA – August 28, 2017 – Medtronic plc (NYSE:MDT) today announced its intent […]
Recent
Xentria Announces Exclusive Licensing Agreement with New York University to Advance a Disease-Modifying Cardiovascular Therapy Globally
Conavi Medical Reports Fiscal 2024 Financial Results and Operational Highlights
DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care
Popular
- No commented posts yet